Related Experiment Videos
Neuroprotective therapy for HIV dementia.
Jadwiga Turchan1, Ned Sacktor, Valerie Wojna
1Department of Neurology, Johns Hopkins University, Baltimore, MD 21287, USA.
Current HIV Research
|March 31, 2004
Summary
Effective antiretroviral therapy alone does not prevent HIV dementia. New neuroprotective therapies are crucial for preventing and treating this condition, guiding future clinical trials and drug development.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- HIV-associated dementia (HAD) persists despite effective antiretroviral therapy (ART).
- Understanding the neuropathogenesis of HIV infection is advancing.
- Neuroprotective therapies are needed alongside ART for HAD prevention and treatment.
Purpose of the Study:
- To discuss the rationale and pathophysiological mechanisms for developing neuroprotective therapy for HAD.
- To review placebo-controlled clinical trials of neuromodulatory/neuroprotective agents in HAD patients.
- To review potential new treatments for HAD based on experimental literature.
Main Methods:
- Review of existing literature on HIV neuropathogenesis.
- Analysis of outcomes from placebo-controlled clinical trials for HAD.
- Evaluation of experimental studies for novel therapeutic targets.
Main Results:
- ART alone is insufficient for preventing HAD.
- Neuromodulatory and neuroprotective therapies have been investigated with varying outcomes.
- Experimental data suggests several potential avenues for new HAD treatments.
Conclusions:
- Adjunctive neuroprotective therapy is essential for managing HAD.
- This review provides a guide for future clinical trials and drug development in HAD.
- Further research is needed to identify and validate effective neuroprotective strategies.